Status:
COMPLETED
IL-7 Receptor Polymorphisms and Immune Recovery With HAART
Lead Sponsor:
The Alfred
Collaborating Sponsors:
National Health and Medical Research Council, Australia
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
The aim is to investigate the hypothesis that IL7-receptor polymorphisms contribute to the differential immune recovery of CD4 + T cells following HAART
Detailed Description
AIM: To examine the association between the four haplotypes of IL-7Rα gene and a cohort of HIV infected patients who have commenced HAART with varying CD4+ T lymphocyte responses. METHODS: IL-7Rα gen...
Eligibility Criteria
Inclusion
- Men or women at least 18 years of age
- First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals
- Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of ≤ 500 copies/mL on bDNA testing (versions 2 and 3) and \<400 copies/ml measured by RT-PCR assay by 6 months treatment.
- CD4 cell count \<500 at commencement of HAART
- Measurement of CD4+ cell count on at least 3 time points, in the 12 months post commencement of HAART.
Exclusion
- Exclude patients treated for HIV seroconversion illness
- Exclude patients on immunomodulatory therapy such as IL-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00168207
Start Date
May 1 2005
End Date
May 1 2009
Last Update
January 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Alfred Hospital, Commercial Road
Melbourne, Victoria, Australia, 3004